Your session is about to expire
← Back to Search
Chiauranib for Advanced Cancers (SCLC Trial)
SCLC Trial Summary
This trial is testing a new cancer drug. In the first part of the trial, the dose of the drug is gradually increased to find out what the best dose is. In the second part of the trial, all patients receive the best dose of the drug to see how well it works.
SCLC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSCLC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SCLC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of cancer.I must continue taking certain medications during the study.You currently have problems with using drugs or alcohol.I have been treated with specific inhibitors before.I understand and can follow the study's requirements.I have a tumor that can be measured and has grown after treatment.I can and will use effective birth control during and for 12 weeks after the study.My cancer has returned or hasn't responded to standard treatments.I am receiving treatment for interstitial lung disease.I had a major surgery recently.My blood tests, liver and kidney function, and clotting ability are within normal ranges.I have major issues with my digestive system.I have serious heart problems that are not under control.I agree to use condoms during the study and for 12 weeks after.I have had a blood clot in my leg or lung before screening.I have uncontrolled fluid buildup in my chest, heart, or abdomen.I have had a condition where my lymphocytes grow abnormally.I am currently experiencing active bleeding or have a high risk of bleeding in my stomach or intestines.I do not have active infections, hepatitis B or C, HIV/AIDS, or other serious infectious diseases.I am 18 years old or older.I haven't had any cancer except for skin cancer in the last 5 years.I have not had cancer treatment recently.I am experiencing moderate to severe side effects from past treatments.I am fully active or restricted in physically strenuous activity but can do light work.You have a high amount of protein in your urine, as shown by a urine test.I have or had other types of cancer.I need treatment for my brain metastases.
- Group 1: Study arm (35 mg)
- Group 2: Study arm (50 mg)
- Group 3: Study arm (65 mg)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many test subjects are participating in this experiment?
"Ultimately, 36 people that fit the clinical study's inclusion criteria are required in order for it to proceed. The sponsor, Chipscreen Biosciences, Ltd., will be managing patient recruitment from different locations; these include Sarah Cannon Research Center in Nashville and Gabrail Cancer Center Research in Canton, Ohio."
Are researchers only testing this on adults, or are minors included in the study as well?
"According to the age parameters set out in this clinical trial, any person aged 18 or older but no more than 75 years old may participate."
Are we still able to enroll new patients in this research project?
"The listed clinical trial on clinicaltrials.gov is currently seeking patients. This study was first made public on 8/26/2022 and the information was last updated on 10/25/2022."
What are the goals that this clinical trial is looking to achieve?
"According to the sponsor of this clinical trial, Chipscreen Biosciences, Ltd., the primary outcome being measured is incidence and characteristics of DLTs over a 34 day period. Additionally, this study will be evaluating secondary outcomes like accumulation ratio (PK Profile), Area under the plasma concentration-time curve (AUC0-t) (PK Profile), and Maximum plasma concentration (Cmax) (PK Profile)."
Share this study with friends
Copy Link
Messenger